Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy - Induced increases in CD4+ cell count: A randomized, double-blind, placebo-controlled trial

Annals of Internal Medicine

Volumn 133, Issue 7, 2000, Pages 493-503

  Currier, J S ^a   Williams, P L ^a   Koletar, S L ^a   Cohn, S E ^a   Murphy, R L ^a   Heald, A E ^a   Hafner, R ^a   Bassily, E L ^a   Lederman, H M ^a   Knirsch, C ^a   Benson, C A ^a   Valdez, H ^a   Aberg, J A ^a   McCutchan, J A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; AZITHROMYCIN; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; INFECTION RISK; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

EID: 0034601814     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-133-7-200010030-00008     Document Type: Article

References (41)

1. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA)
2. Clarithromycin or rifabutin alone or in combination for the primary prevention of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. 196/Terry Beirn Community for Clinical Research on AIDS 009 Protocol Team
3. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group
4. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome
5. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
6. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study. Swiss HIV Cohort Study
7. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997
8. Risk of new AIDS diseases in people on triple therapy
9. A controlled trial of two nucleosides analogues plus indinavir in persons with human immunodefidency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trial Group 320 Study Team
10. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA study
11. Correlation of quantitative bone marrow and blood cultures in AIDS patients with disseminated Mycobacterium avium complex infection
12. Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: A randomised trial. California Collaborative Treatment Group
13. Chronic cryptosporidiosis in patients with AIDS: Stable remission and possible eradication after long-term, low dose azithromycin
14. Revised classification system for HIV infection and expanded surveillance definition for AIDS among adolescents and adults
15. Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation
16. Longitudinal data analysis using generalized linear models
17. Mycobacterium avium complex lymph node abscess after use of highly active antiretroviral therapy in a patient with AIDS
18. Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy
19. Focal mycobacterial lymphadenitis following initiation of proteaseinhibitor therapy in patients with advanced HIV-1 disease
20. Mycobacterial lymphadenitis after initiation of highly active antiretroviral therapy
21. Atypical localizations for atypical mycobacteria: A new trend in AIDS patients receiving HAART?
22. Isolated spinal epidural abscess caused by MAC
23. Survival and disease progression according to gender of patients with HIV infection. The Terry Beirn Community Programs for Clinical Research on AIDS
24. Bacterial pneumonia: A significant risk among a subgroup of HIV-infected patients
25. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS
26. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection
27. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy
28. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study
29. Discontinuation of PCP prophylaxis is safe in HIV-infected patients after immunological recovety with HAART: Results of the GESIDA 04/98 study
30. + T-lymphocyte count. Adult/Adolescent Spectrum of HIV Disease Project (ASD)
31. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?
32. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group
33. Discontinuation of chemoprophylaxis against Pneuraocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators
34. It is safe to discontinue secondary prophylaxis for PCP in HIV-infected patients treated with HAART: Results from eight prospective European cohorts
35. Discontinuing primary and secondary PCP prophylaxis in patients who have increased CD4 counts in response to antiretroviral therapy: Preliminary results. ACTG 888
36. Discontinuation of anticytumegalovirus therapy in persons with HIV infection and cytomegalovirus retinitis
37. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T-cells in response to highly active antiretroviral therapy
38. Longlasting remission ot cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients
39. + counts
40. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy
41. Highly active antiretroviral therapy-related immune recover in AIDS patients with cytomegalovirus retinitis